Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
celebrity makeover games
Popular Articles
Burdock Root

The Automation Partnership's First Project To Automate Manufacture Of 3D Tissue Constructs
The Automation Partnership (TAP), a world leader in the design and development of innovative advanced automation for life science applications, announced it is collaborating with world leading academics on the prestigious, Technology Strategy Board funded, RAFT (Rapid Automated Fabrication of Tissues) Project to develop and commercialise novel technology for rapid production of 3D tissues, which have the potential to transform drug discovery and regenerative medicine.
generic viagra online
University Of Rochester Medical Center Receives HANYS' 2009 Community Health Improvement Award
The Healthcare Association of New York State (HANYS) presented its 2009
News of the day
New Research Shows: Neurofeedback Is An 'Evidence-Based' Treatment For ADHD
Neurofeedback - also called EEG Biofeedback - is a method used to train brain activity in order to normalize Brain function and treat psychiatric disorders. This treatment method has gained interest over the last 10 years, however the question whether this treatment should be regarded as an Evidence-Based treatment was unanswered until now. Tomorrow a study will be published in the scientific journal "EEG and Clinical Neuroscience" demonstrating that Neurofeedback can indeed be regarded as an evidence-based treatment for Attention Deficit- / Hyperactivity Disorder (ADHD).
Medical Devices

British Medical Journal Examines Recent Progress In Treating Neglected Diseases

The British Medical Journal examines the outcome of the Drugs for Neglected Diseases initiative meeting held in Nairobi, Kenya, last week. More than 200 international health experts came together to discuss finding therapies for such diseases as visceral leishmaniasis, Chagas disease and sleeping sickness. "Current treatments are often toxic, prohibitively expensive, or difficult to administer in countries with limited res," and "[d]rug companies have little incentive to develop treatments for neglected diseases that mainly affect poor people," the journal writes. Developing countries have "the ability to provide new solutions for neglected diseases, but every day we face an uphill battle to find home grown capacity for research and development into diseases that affect our poor," said Monique Wasunna of the Kenya Medical Research Institute, adding, "By working together in regional, needs-driven research platforms, we have been able to do more in the past five years than had been done in the previous 20 years." The article examines the recent progress in the area of neglected diseases research around the world, including new treatment options for disease and partnerships for drug discovery and development (Tanne, 6/29). WHO Experts To Discuss Ways To Fund Neglected Disease Research, Drug Development Intellectual Property Watch explores ways to pay for research and clinical trials for treatments of neglected diseases, "even when the consumer demand is small and [the] constituents poor." The topic will be front and center during a meeting of the Expert Working Group on Research and Development Financing, "which is seen by many governments and nongovernmental organisations as a key outcome of the WHO global strategy and plan of action on public health, innovation and intellectual property" (Mara, 6/29). This information was reprinted from globalhealth.kff.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives and sign up for email delivery at globalhealth.kff.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009